- Home
- ABVC vs MREO Comparison
ABVC vs MREO Comparison
Compare ABVC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABVC | MREO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 59.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABVC | MREO |
|---|---|---|
| Price | $1.64 | $0.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 56.9K | ★ 5.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $735.18 | N/A |
| Revenue Next Year | N/A | $6,363.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.20 |
| 52 Week High | $5.48 | $3.05 |
Technical Indicators
Market Signals| Indicator | ABVC | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 31.13 | 36.60 |
| Support Level | $1.53 | $0.36 |
| Resistance Level | $1.76 | $0.44 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 15.79 | 46.51 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).